Ocumension Therapeutics (HKG:1477) said Friday that the Chinese healthcare regulator approved its new drug application for OT-301, its proposed treatment for glaucoma or ocular hypertension-related complications, according to a same-day bourse filing.
The pharmaceutical company said the approval follows the completion of the Mont Blanc and Denali trials of OT-301, in which the treatment achieved key study goals.
The company's shares are down 2.8% in afternoon trading on the HKEX.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.